Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs Quetiapine in TRD
NCT04338321Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, single-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at 8 weeks. Started Aug 2020; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04338321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338321.